Puoti
Dig Dis 2007;25: [277] [278] 278 recent international multicenter, randomized study [20] using PEG-interferon-␣ 2a (180 g weekly) plus ribavirin (800 mg daily) for 24 or 48 weeks, the overall sustained response rate was 30% in patients treated for 24 weeks and 52% in those treated for 48 weeks [20] . In carriers with genotype 1b the response rates were 13 and 40% respectively, while in those harboring genotype 2-3 response rate ranged from 72% (24 weeks) to 78% (48 weeks).
Given the efficacy of the new treatments, which soon became the standard of care for CHC, the 2002 NIH Consensus Development Conference suggested that the issue of whether or not to treat subjects with PNALT should be re-evaluated, and that the issue at hand should be whether or not patients with mild disease should be treated [19] . ALT levels may have less importance in deciding who should be treated [19] . Many other factors might influence the decision to treat, such as the age of the patient, HCV genotype, liver histology, patient's motivation, symptoms, extrahepatic manifestations, comorbid illness.
In agreement with the most recent guidelines and recommendations for the management of hepatitis C [21] , it could be suggested that in clinical practice young patients infected with 'easy-to-treat' HCV genotypes (HCV-2 or HCV-3), highly motivated and without contraindication may be treated without histological assessment considering the very high rate of SVR that can be achieved with 24 weeks of PEG-IFN plus ribavirin and the excellent safety profile. On the other hand, initiation of antiviral therapy might still be decided mainly on the basis of histological findings by taking a diagnostic liver biopsy in HCV patients with PNALT older than 50 years or infected with 'difficult-to-treat' genotypes, with long-lasting infection or with some relative contraindication. In these clinical settings, treatment should be proposed mainly for cases with significant liver disease (fibrosis stage F2). Finally, a strategy of non-intervention might be preferred in HCV patients with PNALT who are above the age of 60-65 years or have major contraindication to antiviral therapy or are reluctant to be treated.
